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Despite rotavirus vaccination, diarrhea remains a leading 
cause of child mortality. We collected stool specimens from 
684 children <5 years of age hospitalized with diarrhea (cases) 
and 527 asymptomatic community controls for 4  years after 
rotavirus vaccine introduction in Malawi. Specimens were 
tested for 29 pathogens, using polymerase chain reaction 
analysis. Three or more pathogens were detected in 71% of 
cases and 48% of controls. Pathogens significantly associated 
with diarrhea included rotavirus (in 34.7% of cases and 1.5% 
of controls), enteric adenovirus (in 29.1% and 2.7%, respec-
tively), Cryptosporidium (in 27.8% and 8.2%, respectively), 
heat-stable enterotoxin-producing Escherichia coli (in 21.2% 
and 8.5%, respectively), typical enteropathogenic E.  coli (in 
18.0% and 8.3%, respectively), and Shigella/enteroinvasive 
E. coli (in 15.8% and 5.7%, respectively). Additional interven-
tions are required to prevent diarrhea due to rotavirus and 
other common causal pathogens.
Keywords. Gastroenteritis; diarrhea; children; PCR; rota-
virus; case-control; Malawi.
The introduction of rotavirus vaccines into childhood immu-
nization programs across Africa has reduced the incidence of 
rotavirus-associated hospitalizations, with a recent popula-
tion-based study from Malawi providing the first evidence of 
the vaccines’ impact on infant diarrheal deaths [1]. However, 
the contribution of bacterial, parasitic, and other viral causes 
of diarrhea among rotavirus-vaccinated African populations is 
not well understood [2, 3].
Malawi is a low-income country in sub-Saharan Africa. 
Among adults, it has one of the highest prevalence rates of 
human immunodeficiency virus (HIV) infection, with or with-
out AIDS, globally; 17.8% of women 15–49 years of age living 
in urban Malawi are infected with HIV [4]. In children <5 years 
of age, the mortality rate is 55 cases/1000 live births, with a high 
prevalence of stunting (37%).
Monovalent human rotavirus vaccine (Rotarix) was 
introduced into Malawi’s national immunization schedule 
in October 2012. At the Malawi-Liverpool-Wellcome Trust 
Clinical Research Programme in Blantyre, Malawi, we have 
examined the effectiveness of Rotarix against rotavirus 
diarrhea requiring hospitalization [5]. Our diarrhea surveil-
lance platform is centered on a large urban hospital (Queen 
Elizabeth Central Hospital [QECH]) and includes collection 
of clinical, demographic, and socioeconomic data, com-
bined with documentation of rotavirus vaccine status and 
stool specimen collection.
We aimed to understand the etiology of severe acute child-
hood gastroenteritis following rotavirus vaccine introduction in 
Malawi. We therefore undertook a case-control study to exam-
ine the prevalence of enteric pathogens among hospitalized 
children <5 years of age with diarrhea, compared with findings 
for diarrhea-free children in the community.
METHODS
Study Setting
The study was conducted in Blantyre, a district in southern 
Malawi with a population of approximately 1.3 million peo-
ple. QECH provides free healthcare to residents of urban 
and rural areas of Blantyre District and is the only free, gov-
ernment-run inpatient referral center in southern Malawi. 
Monovalent rotavirus vaccine is administered according to 
the World Health Organization–recommended schedule of 6 
and 10 weeks of age. Vaccine coverage increased rapidly fol-
lowing introduction and has exceeded 90% among age-eligi-
ble children since 2014 [1, 6].
Symptomatic Hospitalized Cases
Subject enrollment and specimen collection were under-
taken as part of our existing research program [5]. Stool 
specimens were collected from November 2012 to December 
2015 from children <5 years of age with acute gastroenteri-
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gastroenteritis was defined as the passage of ≥3 loose stools 
within a 24-hour period commencing <14  days before 
enrollment. We obtained demographic, clinical, and anthro-
pometric data through parental interview, physical exam-
ination, and review of medical notes. Maternal HIV testing 
was undertaken according to national guidelines, as previ-
ously reported [5]. Disease severity was measured using the 
Vesikari scoring system; a score of ≥11 (out of 20) indicates 
severe disease.
Asymptomatic Community Controls
Stool specimens were collected from children in the commu-
nity who reported no diarrhea for at least 7  days (hereafter, 
“controls”). These composed a random sample of community 
controls recruited between April 2013 and December 2016 into 
case-control studies of rotavirus vaccine effectiveness, in which 
controls were matched by age and district of residence to cases 
with confirmed rotavirus diarrhea [5, 6].
Laboratory Testing
Fecal specimens were stored at −80ºC. We tested for 29 dif-
ferent enteric pathogens in fecal specimens, using a 384-well 
singleplex real-time polymerase chain reaction (PCR) analysis 
platform, the enteric Taqman Array Cards (TAC) [7]. The TAC 
method performance has been previously described; samples 
were classified as pathogen positive at a cycle threshold of <35 
[7]. Detection above this threshold is not reproducible and is 
unlikely to be clinically significant [7].
Analysis
Since the introduction of rotavirus vaccination, norovirus has 
gained increasing recognition as a significant pathogen asso-
ciated with diarrhea in children [8]. We therefore based our 
sample size calculation on the norovirus prevalence. Assuming 
prevalence proportions of 10% among hospitalized cases with 
gastroenteritis and 5% among asymptomatic community con-
trols [9], we calculated that, for 90% power, 621 samples per 
group were needed to show a significant difference in preva-
lence between cases and controls (α = 0.05). Pathogen preva-
lence among cases and controls was compared using the χ2 test 
or the Fisher exact test. Differences between continuous vari-
ables were tested using the Student t test or the Wilcoxon rank 
sum test.
Adjusted attributable fractions (AFs) were calculated for 
pathogens that had a greater prevalence among cases as com-
pared to controls. Using a similar approach to that in the Global 
Enteric Multicentre Study (GEMS) [10], multivariable logistic 
regression was used to calculate odds ratios (ORs) for each 
pathogen detected, adjusting for presence of other pathogens, 
age in months and month of recruitment. Case or control sta-
tus was the outcome variable and the predictors were indicator 
variables representing the presence or absence of each patho-
gen. We then calculated AFs for pathogens that were significant 
(P < .05) in multivariable logistic regression. Calculation of AFs 
was as follows:






AFi, attributable fraction for pathogen i among cases
ORi, adjusted odds ratio for pathogen i among cases
where Prevalencei denotes the prevalence of pathogen i among 
cases. Analyses were performed using R version 3.3.5 (R 
Development Core Team, Vienna, Austria), with AFs and asso-
ciated 95% confidence intervals (CIs) calculated using boot-
strap resampling in the “attribrisk” package.
Ethics
Approval was obtained from the Malawi National Health 
Sciences Research Committee (protocol 837)  and from the 




A total of 1211 fecal samples were analyzed, comprising 684 sam-
ples from cases and 527 samples from controls (Supplementary 
Table 1). The median age was 10.7 months (interquartile range 
[IQR], 7.9–15.4 months) and 12 months (IQR, 9.2–18.7 months) 
for cases and controls, respectively. Rotavirus vaccine status was 
established for 419 of 451 cases who met the age-based eligibility 
criterion for vaccination (of whom 97% had received ≥1 dose) 
and for 375 of 400 controls who met the age-based eligibility 
criterion (of whom 95% were vaccinated). Maternal HIV status 
was determined for 665 of 684 cases (97%), of whom 18% were 
HIV exposed. Mid-upper arm circumference was lower in cases 
(median, 13.0 cm), compared with controls (15.3 cm). Among 
cases, 60 (9%) were severely malnourished (mid-upper arm cir-
cumference, < 11.5 cm), compared with 2 controls (0.4%). The 
Vesikari score among cases ranged from mild (score, 1) to very 
severe (score, 20), with a median score of 13 (IQR, 10–15).
Pathogen Prevalence
A positive PCR result for at least 1 pathogen was returned 
for 641 samples (94%) from cases and 390 (74%) from con-
trols (P  <  .001; Supplementary Table 1). Pathogens that were 
more frequently identified in cases than in controls included, 
in decreasing order of prevalence (cases/controls), rota-
virus (34.7% of cases vs 1.5% of controls), adenovirus 40/41 
(29.1% vs 2.7%), Cryptosporidium (27.8% vs 8.2%), heat-stable 
enterotoxin-producing Escherichia coli (ST-ETEC; 21.2% vs 
8.5%), typical enteropathogenic E. coli (EPEC; 18.0% vs 8.3%), 
Shigella/enteroinvasive E. coli (EIEC; 15.8% vs 5.7%), Salmonella 
Typhimurium (2.3% vs 0.4%), and Vibrio cholerae (1.3% vs 0%; 
Table 1). Pathogen prevalence proportions stratified by age 
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frequently detected in cases, compared with controls (7.3% vs 
13.9%). Enteroaggregative E. coli (EAEC), Campylobacter, and 
norovirus were frequently detected in both cases and controls. 
Pathogens with the highest AFs were rotavirus, adenovirus 
40/41, and Cryptosporidium (Table 1). Median Vesikari scores 
stratified by pathogen ranged from 11 to 14.5 (Supplementary 
Figure 1).
Pathogen Distribution, by Age
The median age of Giardia-positive cases (15.6  months) was 
significantly higher than that of Giardia-positive controls 
(11.7 months; P = .014). For the following organisms, the me-
dian age of pathogen-positive cases was significantly lower 
than that of pathogen-positive controls: Campylobacter (10.9 
vs 13.8  months; P  <  .001), LT-ETEC (10.8 vs 12.0  months; 
P = .044), and atypical EPEC (11.3 vs 12.4 months; P = .030). 
There was no difference in age between cases and controls for 
the remaining pathogens (Supplementary Figure 2).
Mixed Infections
Among pathogen-positive samples, a single pathogen was 
detected in fecal samples from 78 cases (11%) and 42 controls 
(8%). Cases had a significantly higher number of pathogens 
(mean  [±SD], 3.65  ± 2.11 pathogens) as compared to con-
trols (mean  [±SD].  2.42  ± 1.96 pathogens), with ≥3 patho-
gens detected in 71% of cases, compared with 48% of controls. 
Enteroaggregative E.  coli (EAEC) was identified in 51.8% 
of cases and 47.8% of controls. The most frequent coinfec-
tions involving EAEC were with rotavirus, adenovirus 40/41, 
Cryptosporidium, ST-ETEC, and typical EPEC, among cases, 
and with Campylobacter, atypical EPEC, Giardia, and LT-ETEC, 
among controls (Figure 1).
Table 1. Prevalence and Attributable Fractions (AFs) for Enteric Pathogens Among Children Hospitalized With Diarrheal Disease (Cases) and Asymptomatic 
Children From the Community (Controls)
Pathogen Cases, No. (%) (n = 684) Controls, No. (%) (n = 527) P Adjusted AF ± SE, % 95% CI
EAEC 354 (51.8) 252 (47.8) .193 … …
Rotavirus 237 (34.6) 8 (1.5) <.001 34.2 ± 0.018 31.1–38.0
Adenovirus 40/41 199 (29.1) 14 (2.7) <.001 27.7 ± 0.018 24.5–31.4
Cryptosporidium 190 (27.8) 43 (8.2) <.001 22.3 ± 0.023 18.2–27.2
ST-ETEC 145 (21.2) 45 (8.5) <.001 12.7 ± 0.030 7.2–18.1
Typical EPEC 123 (18.0) 44 (8.3) <.001 6.6 ± 0.037 0–12.2
Any Campylobacter 113 (16.5) 102 (19.4) .229 … …
Shigella/EIEC 108 (15.8) 30 (5.7) <.001 10.8 ± 0.021 6.5–14.9
Norovirus 83 (12.1) 45 (8.5) .054 7.0 ± 0.019 2.8–10.6
Atypical EPEC 77 (11.3) 80 (15.2) .054 … …
LT-ETEC 68 (9.9) 71 (13.5) .069 … …
Sapovirus 64 (9.4) 34 (6.5) .083 … …
Giardia 50 (7.3) 73 (13.9) <.001 … …
Enterocytozoon bieneusi 31 (4.5) 21 (4.0) .747 … …
Any Salmonella 30 (4.4) 5 (0.9) .001 … …
Aeromonas 27 (3.9) 10 (1.9) .059 … …
Salmonella Typhimurium 16 (2.3) 2 (0.4) .007 1.8 ± 0.009 .0–3.2
Encephalitozoon intestinalis 15 (2.2) 20 (3.8) .14 … …
Cyclospora 13 (1.9) 4 (0.8) .138 … …
Astrovirus 12 (1.8) 13 (2.5) .509 … …
Entamoeba histolytica 10 (1.5) 8 (1.5) 1 … …
Vibrio cholerae 9 (1.3) 0 (0.0) .006 … …
Salmonella Typhi 8 (1.2) 2 (0.4) .201 … …
Strongyloides 7 (1.3) 10 (1.5) .845 … …
Necator 5 (0.7) 1 (0.2) .241 … …
STEC 5 (0.7) 1 (0.2) .241 … …
Ascaris 4 (0.6) 5 (0.9) .514 … …
Isospora 3 (0.4) 1 (0.2) .637 … …
Salmonella Enteritidisa 0 (0.0) 0 (0.0) NA … …
Trichurisa 0 (0.0) 1 (0.2) .435 … …
Ancyclostomaa 0 (0.0) 0 (0.0) NA … …
Pathogens are listed in order of decreasing prevalence among cases.
Abbreviations: CI, confidence interval; EAEC, enteroaggregative Escherichia coli; EIEC, enteroinvasive Escherichia coli; EPEC, enteropathogenic Escherichia coli; LT-ETEC, heat-labile entero-
toxin-producing Escherichia coli; SE, standard error; STEC, Shiga toxin–producing Escherichia coli; ST-ETEC, STh- or STp-producing enterotoxigenic Escherichia coli.
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DISCUSSION
We have shown that, following rotavirus vaccine introduction 
in Malawi, rotavirus remains the leading pathogen detected in 
children <5 years of age hospitalized because of diarrhea. This 
is in agreement with data from 2 smaller studies, including one, 
performed in Tanzania, that assessed 146 diarrhea cases in 2015 
and another, reported by the Global Rotavirus Surveillance 
Network, that analyzed a total of 327 samples collected from 10 
African countries between 2013 and 2014 [2, 3]. The prevalence 
of rotavirus shedding in asymptomatic children reported in this 
study (1.5%) is lower than reported previously in Malawi [11]. 
This may be the consequence of a high level of rotavirus vaccine 
coverage, which reduced rotavirus transmission in the commu-
nity and potentially yielded indirect benefits [6].
Adenovirus 40/41 was significantly associated with hospitali-
zation for diarrheal disease, in contrast with the Tanzanian and 
Global Rotavirus Surveillance Network studies, which reported 
a modest AF for this pathogen [2, 3]; however, the AFs calcu-
lated by these studies relied on samples from asymptomatic indi-
viduals in the community that were collected during the GEMS 
study, before rotavirus vaccine introduction [10]. Furthermore, 
pathogen-specific AFs should be interpreted with caution, since 
the relationship between organism load, disease severity, and 
duration of shedding are not well defined for pathogens other 
than rotavirus. Nevertheless, the high prevalence of adenovirus 
40/41 among cases, combined with a low prevalence among 
asymptomatic children, suggests an important role for this 
pathogen in severe diarrhea in Malawian children. Our data are 
supported by recent reanalysis of the GEMS and MAL-ED (The 
Aetiology, Risk Factors, and Interactions of Enteric Infections 
and Malnutrition and the Consequences for Child Health) 
studies, which highlighted the importance of adenovirus 40/41 
among children with diarrhea [12, 13].
Cryptosporidium was frequently associated with hospitaliza-
tion for diarrhea in Malawian children, with a higher preva-
lence than reported in studies conducted elsewhere [2, 3, 10, 
12, 13]. Cryptosporidium diarrhea is associated with 4.2 million 
disability-adjusted life-years (DALYs) lost globally and a loss of 
7.85 million DALYs after accounting for the negative impact it 
has on growth [14]. These data highlight the need to prioritize 
effective treatment and prevention of Cryptosporidium infec-
tion in Malawi and other low-income countries that have high 
rates of stunting and HIV/AIDS, to reduce the burden of diar-
rheal disease and its associated long-term health consequences.
We also identified ST-ETEC, typical EPEC, and Shigella/
EIEC as important pathogens associated with hospitalization 
for diarrheal disease, in line with previous reports [2, 12, 13]. 
Other pathogenic E. coli were also commonly detected. EAEC 
was found in nearly half of infants, regardless of the presence of 
diarrhea, and was frequently identified in coinfections among 
both cases and controls. Although EAEC does not appear to be 
associated with acute diarrhea in this or previous studies [2, 3, 
10], its presence with ≥2 pathogens may have a negative impact 























































































































































































































































































































































































































































Figure 1. Coinfections among children hospitalized with diarrheal disease (cases) and asymptomatic children from the community (controls). Percentages of cases and 
controls coinfected with the specified pathogens are shown and were calculated by dividing the number of infections with both pathogen A (row) and B (column) by the 
denominator for the relevant group (ie, either total number of cases or total number of controls). EAEC, enteroaggregative Escherichia coli; E. bieneusi, Enterocytozoon 
bieneusi; E. histolytica, Entamoeba histolytica; EIEC, enteroinvasive Escherichia coli; E. intestinalis, Encephalitozoon intestinalis; EPEC, enteropathogenic Escherichia coli; 
LT-ETEC,  heat-labile enterotoxin-producing Escherichia coli; S. Enteriditis, Salmonella Enteriditis; STEC,  Shiga toxin–producing Escherichia coli; ST-ETEC,  STh- or STp-
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with hospitalization for diarrheal disease, the high prevalence 
of Campylobacter and Giardia among asymptomatic children in 
Malawi may result in growth faltering [16].
In some high-income settings, norovirus has emerged as the 
leading cause of severe diarrhea in children following rotavirus 
vaccine introduction [15]. However, we did not document any 
change in norovirus prevalence since rotavirus vaccine intro-
duction in Malawi; norovirus was identified in 12.1% of chil-
dren hospitalized with diarrhea, compared with 11.3% in the 
prevaccine period [16].
Our study has limitations. First, cases were slightly younger 
than controls; we therefore adjusted for age and month of 
recruitment in the analyses. We calculated AFs on the basis of 
the binary presence or absence of pathogens, similar to the orig-
inal GEMS study [10]. This method differs from those used for 
the reanalysis of data from the GEMS and MAL-ED studies [13, 
16], in which pathogen quantity was included in the model as 
a quadratic term. We chose not to use this approach, because, 
unlike longitudinal studies, the duration of pathogen shedding 
is not quantifiable in case-control studies and because patho-
gen quantity will be variably associated with disease. A further 
consideration is our inclusion of cases from November 2012 
to March 2013, prior to control recruitment, to achieve the 
required sample size. In sensitivity analysis, exclusion of the 
early cases did not significantly alter the point prevalence of any 
pathogen (data not shown).
Rotavirus remains the most common cause of severe diar-
rhea requiring hospitalization among children in Malawi, high-
lighting the importance of identifying strategies to improve 
rotavirus vaccine performance in this and similar low-in-
come countries with a high disease burden. Adenovirus 40/41, 
Cryptosporidium, ST-ETEC, typical EPEC, and Shigella/EIEC 
are significant additional contributors to the burden of gas-
trointestinal disease in this population. Public health efforts, 
including vaccine development, should target these pathogens.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
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